⚡
CHARGED ALPHA
Stock Detail
Stock Library / BMY
BMY Healthcare

Bristol-Myers Squibb

Live stock metrics, chart context, a quarter-by-quarter YouTube archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Company Website Back to Library

Library coverage

Quarters tracked
1
YouTube quarters live
0
Latest video
Pending
YouTube available
No
Current price
$60.17
+1.22 (+2.07%)
Trailing / Forward P/E
17.39x
Forward: 9.81x
Market cap / Volume
—
Volume: —
Revenue / Earnings Growth
1.3%
Earnings: 1392.1%
Margins
28.2% op
Gross: 72.6% · Net: 14.6%
Balance sheet
1.25x current
Debt / Equity: 255.0
52-week range / Beta
$42.52 - $62.89
Beta: 0.27
Analyst target
$63.04
Upside: 4.8%
Cash / shareholder return
9.07% FCF yield
Dividend yield: 4.22%

Company context

Industry: Drug Manufacturers - General
Country: United States
Employees: —
Price to book: 6.63x
Return on equity: 40.4%
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Price chart

Market context for BMY

Competitive view

BMY vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

Bristol-Myers Squibb
BMY
Latest video
YouTube link pending
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Balance-sheet leverage is elevated, so investors should watch refinancing costs and how much flexibility management really has.
UnitedHealth Group
UNH
YouTube
Latest video
Q1 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Merck & Co.
MRK
YouTube
Latest video
Q1 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Market Cap
More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.
BMY
$122.85B
Bristol-Myers Squibb
UNH
$294.66B
UnitedHealth Group
MRK
$294.39B
Merck & Co.
Trailing P/E
Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.
BMY
17.4x
Bristol-Myers Squibb
UNH
24.5x
UnitedHealth Group
MRK
16.4x
Merck & Co.
Forward P/E
Forward P/E is often a better read on what investors are paying for the next year of earnings power.
BMY
9.8x
Bristol-Myers Squibb
UNH
16.1x
UnitedHealth Group
MRK
12.2x
Merck & Co.
Revenue Growth
Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.
BMY
1.3%
Bristol-Myers Squibb
UNH
12.3%
UnitedHealth Group
MRK
5.0%
Merck & Co.
Earnings Growth
Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.
BMY
1392.1%
Bristol-Myers Squibb
UNH
-99.9%
UnitedHealth Group
MRK
-19.3%
Merck & Co.
Operating Margin
Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.
BMY
28.2%
Bristol-Myers Squibb
UNH
0.3%
UnitedHealth Group
MRK
32.8%
Merck & Co.
Gross Margin
Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.
BMY
72.6%
Bristol-Myers Squibb
UNH
18.5%
UnitedHealth Group
MRK
77.2%
Merck & Co.
Net Margin
Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.
BMY
14.6%
Bristol-Myers Squibb
UNH
2.7%
UnitedHealth Group
MRK
28.1%
Merck & Co.
Return on Equity
ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.
BMY
40.4%
Bristol-Myers Squibb
UNH
12.5%
UnitedHealth Group
MRK
36.9%
Merck & Co.
Free Cash Flow Yield
Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.
BMY
9.1%
Bristol-Myers Squibb
UNH
4.7%
UnitedHealth Group
MRK
4.0%
Merck & Co.
Debt to Equity
Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.
BMY
254.98x
Bristol-Myers Squibb
UNH
81.62x
UnitedHealth Group
MRK
95.96x
Merck & Co.
Current Ratio
A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.
BMY
1.25x
Bristol-Myers Squibb
UNH
0.79x
UnitedHealth Group
MRK
1.54x
Merck & Co.
Beta
Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.
BMY
0.27
Bristol-Myers Squibb
UNH
0.41
UnitedHealth Group
MRK
0.28
Merck & Co.
Dividend Yield
Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.
BMY
4.2%
Bristol-Myers Squibb
UNH
2.8%
UnitedHealth Group
MRK
2.8%
Merck & Co.
Analyst Upside
Higher analyst upside suggests the Street still sees room between current price and consensus fair value.
BMY
4.8%
Bristol-Myers Squibb
UNH
11.0%
UnitedHealth Group
MRK
9.0%
Merck & Co.

YouTube timeline

Quarterly archive for BMY

Each row is one quarter. Only the YouTube link is shown here for now.

Q1 2026
Video pending
Pending link pending
Quarterly earnings-analysis entry for Bristol-Myers Squibb. Use the YouTube link on the right to jump straight into that quarter's video when it is live.
No verified YouTube link yet